ZygoFix Receives CE Clearance for its zLOCK Spinal Fusion System

ZygoFix has obtained CE mark for its minimally invasive screwless spinal fusion system for the treatment of chronic back pain, the zLOCK Spinal Fusion System.

ZygoFix completed the certification process and received CE mark for its zLOCK Spinal Fusion System for lumbar spine after demonstrating its safety and efficacy in clinical studies. Together with this certification, ZygoFix also received ISO13485 certification.

The zLOCK system’s miniature 3D-printed implant utilizes the spine’s anatomy for spinal stability, rather than traditional external screw-based stabilization. Its unique features combine rigid and bendable elements that enable the implant to withstand loads applied through the spine, while conforming to each patient’s anatomy during implantation. The procedure eliminates risks associated with improperly placed screws, is less invasive (2 versus 6 incisions), simple to use, and suitable for outpatient implantation.

The zLOCK system has been in clinical use for more than three years in Hungary and Israel with high levels of patient and physician satisfaction.

ZygoFix CEO Ofer Levy remarks: “Receiving CE Mark is a key event for the zLOCK system as a minimally invasive and safer solution for back pain sufferers. ZygoFix is opening a multi-center pivotal study in the EU to collect further clinical data.”

SourceZygoFix
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Led by researchers at NYU Grossman School of Medicine, the study results add to evidence that neighboring brain regions, the inferior frontal gyrus and the motor cortex, play an important role in such planning before words are said aloud. Both are part of the folded top layers of the brain, or cerebral cortex, which has long been known to control the muscle (motor) movements in the throat and mouth needed to produce speech. Less clear until now was how closely these regions determine the mix of sounds and words people want to say aloud, the authors report.
PolarisAR describes STELLAR Knee as a mixed-reality surgical navigation platform that guides TKA procedures by displaying measured and computed data overlaid directly in a 3D environment. The mixed-reality system acts as a spatial computer, creating continuous data exchange between the surgeon and the software to help enhance surgical decision-making while simplifying operating room workflow.
This February, the first enrolled patient underwent open surgical aortic arch reconstruction at the University of Pennsylvania, Presbyterian Medical Center, Philadelphia, PA.  During the surgery, the Duett Vascular Graft System was successfully deployed to connect the native left common carotid artery to the surgical graft.
"Our ultra low insertion loss Athermal AWG Multiplexers along with temperature-hardened low-drift AAWG specifically designed for the industrial temperature applications will be marketed aggressively through partnership companies in the East Asia and EU regions after its success in the North America," says Dr. Donald Yu, CMO of POINTek, who runs global marketing operations from Los Angeles, California.
AUX-001 is an innovative, once-daily, extended-release formulation of Nicorandil. For decades, immediate-release, twice daily Nicorandil has been a cornerstone treatment for chronic angina symptoms outside the US, distinguished by its dual mechanism of action that targets both the micro- and macrovascular coronary artery flow bed, and providing sustained angina symptom relief without the common issue of tachyphylaxis seen with other anti-anginal vasodilators like long-acting nitrates. AUX-001 offers efficacy comparable to conventional anti-anginal medications such as beta-blockers, calcium channel blockers, and long-acting nitrates while also potentially enhancing control of the underlying coronary disease and reducing angina related hospitalizations.

By using this website you agree to accept Medical Device News Magazine Privacy Policy